Biocon launches insulin Glargine in Japan

Mumbai: Biocon announced said it has begun selling insulin Glargine, in disposable pens in Japan, with its partner FUJIFILM Pharma Co, on Friday. This comes close on the heels of receiving approval for its Insulin Glargine from the Japanese regulator last quarter.

Biocon is the first company to enter the biosimilars space and launch it in a highly regulated developed market. It expects to launch similar products in the US and Europe, says a company statement.

The company through its partner aims to capture a significant share of the Japanese Glargine market of $144 million, which is the second largest market outside of North America and Europe, and is largely dominated by disposable pens.

Insulin Glargine BS Injection Kit (FFP) has been developed and manufactured by Biocon, and is being commercialized by FFP in Japan.

There were 7.2 million people with diabetes in Japan in 2015, according to the International Diabetes Federation.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.